« Zurück
Startseite /
Hepatitis B surface antigen (ready-to-use)

Hepatitis B surface antigen (ready-to-use)

ArtNr	18-272-196583
Hersteller	GENWAY
Menge	6 ml
Kategorie	Oncology Antibodies Immunohistochemistry Primary Antibodies By Organ Hepatic Cancer
Typ	Antibody
Applikationen	IHC
Specific against	other
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	GWB-AC3523
Similar products	18-272-196583
Lieferbar
Genway ID:	GWB-AC3523
Isotype:	IgG
Immunogen:	Purified surface antigen of subtype ad/ay.
Specificity:	This antigen reacts with liver cells of the patients infected with Hepatitis type B virus as well as with hepatocellular carcinoma and cirrhosis.
Positive Control:	Infected liver
Target:	Hepatitis B surface antigen
Localization:	Cytoplasmic
Concentration:	ready-to-use Storage
Buffer:	Contains sodium azide
Application Note:	For IHC-P: This antibody has been prediluted and is ready to use. We suggest an incubation period of 30 minutes at RT. Not tested in other applications. Optimal dilutions/concentrations should be determined by the researcher. Cellular
Localization:	Cytoplasmic Hepatitis B Virus (HBV) infection induces a disease state which manifests itself in a variety of ways characterized by the extent of liver damage inflammation and viral persistence. HBV infection is also associated with a 100 fold increased risk of hepatocellular carcinoma and currently infects over 250 million people worldwide. HBV has a partially double stranded 3. 2 kilobase DNA genome which contains four open reading frames. One of these encodes a 154 amino acid protein called the HBx protein. HBx has been shown to be a transcriptional transactivator of both viral and cellular promoters. Lacking a DNA binding domain and nuclear localization signal HBx is believed to exert transcriptional activity through protein-protein interaction.
Function:	The large envelope protein exists in two topological conformations one which is termed \' external\' or Le-HBsAg and the other \' internal\' or Li-HBsAg. In its external conformation the protein attaches the virus to cell receptors and thereby initiating infection. This interaction determines the species specificity and liver tropism. It also assume fusion between virion membrane and cellular membrane. In its internal conformation the protein plays a role in virion morphogenesis and mediates the contact with the nucleocapsid like a matrix protein (By similarity).
Function:	The middle envelope protein plays an important role in the budding of the virion. It is involved in the induction of budding in a nucleocapsid independent way. In this process the majority of envelope proteins bud to form subviral lipoprotein particles of 22 nm of diameter that do not contain a nucleocapsid (By similarity).
Subunit:	Li-HBsAg interacts with capsid protein and with HDV Large delta antigen. Isoform M associates with host chaperone CANX through its pre-S2 N glycan. This association may be essential for M proper secretion (By similarity).
Subcellular Location:	Virion membrane (By similarity).
Domain:	The large envelope protein is synthesized with the pre-S region at the cytosolic side of the endoplasmic reticulum and hence will be within the virion after budding. Therefore the pre-S region is not N-glycosylated. Later a post-translational translocation of N-terminal pre-S and TM1 domains occur in about 50% of proteins at the virion surface. These molecules change their topology by an unknown mechanism resulting in exposure of pre-S region at virion surface. For isoform M in contrast the pre-S2 region is translocated cotranslationally to the endoplasmic reticulum lumen and is N-glycosylated.
Ptm:	Isoform M is N-terminaly acetylated at a ratio of 90% N- and O-glycosylated at the pre-S2 region.
Ptm:	Myristoylated (By similarity). Biotechnology: Systematic vaccination of individuals at risk of exposure to the virus has been the main method of controlling the morbidity and mortality associated with hepatitis B. The first hepatitis B vaccine was manufactured by the purification and inactivation of HBsAg obtained from the plasma of chronic hepatitis B virus carriers. The vaccine is now produced by recombinant DNA techniques and expression of the S isoform in yeast cells. The pre-S region do not seem to induce strong enough antigenic response.
Similarity:	Belongs to the orthohepadnavirus major surface antigen family.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 6 ml

lieferbar

Lieferung vsl. bis 13.11.2025

Express-Lieferung: 1 Tage sparen

Vergleichen

Auf den Wunschzettel

Angebot anfordern